Dec 22, 2020 8:00am EST SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Dec 17, 2020 9:28am EST SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Dec 16, 2020 4:21pm EST SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants
Dec 10, 2020 8:00am EST SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections
Dec 07, 2020 8:00am EST SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
Nov 06, 2020 8:44am EST SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
Oct 21, 2020 8:30am EDT SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020
Oct 14, 2020 8:30am EDT SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
Oct 12, 2020 8:30am EDT SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference
